Zentalis Pharmaceuticals ZNTL
NASDAQ ZNTL
$3.99 -0.12 (-2.80%)
As of: Sep 4, 2026 · 3:59 PM EDT

Zentalis Pharmaceuticals (ZNTL) Revenue (2024)

Zentalis Pharmaceuticals (ZNTL) posted quarterly Revenue of $26.9 million for Q4 2024, down 33.76% quarter-over-quarter from $40.6 million in Q1 2024.

Analysis

Zentalis Pharmaceuticals (ZNTL) Revenue (2024) Analysis & Trends

Zentalis Pharmaceuticals' Revenue history runs 1 years deep, the most recent figure standing at $26.9 million for Q4 2024.

  • In Q4 2024, Revenue changed N/A year-over-year to $26.9 million; the TTM figure through Sep 2025 stood at $26.9 million (down 33.76% YoY), while the FY2024 annual figure was $67.4 million, changed N/A from the prior year.
  • Revenue for Q4 2024 stood at $26.9 million, down from $40.6 million in the prior quarter.
  • The five-year high for Revenue was $40.6 million in Q1 2024, with the low at $26.9 million in Q4 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 3.33 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 4.29 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 1.52 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 145.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1.71 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 1.29 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 674.14 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 425.49 Mn
10 Zentalis Pharmaceuticals 282.81 Mn 282.81 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 26.87 Mn
Mar 31, 2024 40.56 Mn